MedTrace Logo

Ivonescimab in Combination With Docetaxel in Advanced Non-Small Cell Lung Cancer

NCT06928389 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 536

Last updated 2026-04-09

No results posted yet for this study

Summary

This is a Phase 3 Randomized, double-blind, Multicenter Study of Ivonescimab Combined with Docetaxel Versus Placebo Combined with Docetaxel in Patients with Locally advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) that has progressed on or after PD-(L)1 inhibitor-based therapy. The purpose of this study is to evaluate the efficacy and safety of ivonescimab versus placebo, combined with docetaxel in patients with advanced NSCLC.

Conditions

Interventions

DRUG

Ivonescimab, docetaxel

Patients will receive ivonescimab and docetaxel as an IV injection

DRUG

Placebo, docetaxel

Patients will receive placebo and docetaxel as an IV injection

Sponsors & Collaborators

Principal Investigators

  • Caicun Zhou · Shanghai East Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-08
Primary Completion
2027-05-31
Completion
2030-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06928389 on ClinicalTrials.gov